Latest / Stock Movers / Starbucks Denies Acquiring Chipotle, Bristol Myers Falls, Salesforce
Transcript
- 0:00Speaker 1: Let's take a look at some stocks on the move today.
- 0:02Speaker 1: I'm Tim Stanovick, along with Carol Master. Back with us,
- 0:05Speaker 1: Bloomberg News U.S. equities reporter, Matthew Griffin. Hey, Matthew.
- 0:08Speaker 2: Hey, Tim. How's it going?
- 0:09Speaker 1: Good, good. What stocks did you bring us today?
- 0:11Speaker 2: Well, I've been watching Chipotle all day. That's ticker CMG.
- 0:15Speaker 2: It's been extending losses now down almost 5% after Starbucks
- 0:20Speaker 2: said they are not buying the Mexican fast casual chain
- 0:25Speaker 2: Of course, that stock had rallied last week on this
- 0:28Speaker 2: FT report that Starbucks had talked to advisors about a
- 0:30Speaker 2: potential deal to do just that. Now we're seeing a
- 0:34Speaker 2: bit of the deal premium taken out of the stock
- 0:37Speaker 2: and investor attention returned to a somewhat dismal story there.
- 0:41Speaker 2: I mean, the shares are now down 19% this year again.
- 0:46Speaker 1: Can anyone give me a story about why this deal
- 0:48Speaker 1: would make sense?
- 0:49Speaker 3: To food companies? Somebody, a CEO who knows Chipotle like
- 0:54Speaker 3: no other so that if you wanted to create synergies
- 0:57Speaker 3: and cut costs that maybe you could figure it out.
- 0:59Speaker 1: But from a brand identity perspective, like Chipotle is not
- 1:03Speaker 1: recognized as a quote unquote third place where you go
- 1:08Speaker 1: and gather as a community, where you do your homework.
- 1:11Speaker 3: Chipbox, call the company Chipbox.
- 1:13Speaker 1: It just, it just, I'm sorry, Matt. It's just like,
- 1:17Speaker 1: I saw this headline last week. I was like, this makes,
- 1:19Speaker 1: apart from the relationship between like, you know, Brian Nickel
- 1:22Speaker 1: and Scott Boatwright.
- 1:23Speaker 3: Beans, beans and coffee, beans and burritos. I don't know.
- 1:26Speaker 3: I know.
- 1:27Speaker 1: I don't get it.
- 1:28Speaker 3: I don't get it either.
- 1:29Speaker 1: Do any analysts get it?
- 1:30Speaker 2: Analysts? Well, they thought it might make sense for Chipotle
- 1:33Speaker 2: for exactly that reason. Brian Nickel knows the company. He
- 1:36Speaker 2: could engineer a turnaround on all the metrics they're lagging on.
- 1:39Speaker 1: He's busy engineering a turnaround at Starbucks.
- 1:41Speaker 2: Well, that's the exact thing.
- 1:42Speaker 3: That's the big reason why.
- 1:43Speaker 2: Analysts were very concerned about what this would mean for Starbucks,
- 1:48Speaker 2: whether they could focus on two turnarounds at once, one
- 1:50Speaker 2: that is... going well at starbucks but is in kind
- 1:53Speaker 2: of the early days it's kind of.
- 1:54Speaker 3: Like you have one toddler and you're like ah let's
- 1:56Speaker 3: just get pregnant and have another one we're in the
- 1:58Speaker 3: diapers we're in the non-sleeping let's just like roll it
- 2:00Speaker 3: all in okay that feels about right i get it
- 2:03Speaker 3: right and then they're all of a sudden they're both
- 2:05Speaker 3: like five or six and they're off to kindergarten in
- 2:07Speaker 3: first grade and you're like wow.
- 2:08Speaker 1: Okay that's their problem but it's not because when school's
- 2:11Speaker 1: over it's your problem that's.
- 2:12Speaker 2: True well and we're seeing a bit of relief in
- 2:14Speaker 2: starbucks today that's ticker sbux up about a percent and
- 2:17Speaker 2: a half Yeah.
- 2:18Speaker 1: Matthew's like, can we talk about the next stock?
- 2:20Speaker 3: All right, let's go to Bristol, Bristol Myers, BMY.
- 2:23Speaker 2: Yes, that stock is down almost 3% after some, also
- 2:27Speaker 2: you want to talk about confusing situations, some hard to
- 2:30Speaker 2: parse data from a trial of a drug for a
- 2:32Speaker 2: lung disease. That's idiopathic pulmonary fibrosis. And the interesting thing
- 2:37Speaker 2: here is patients on a smaller dose showed statistically significant improvement.
- 2:41Speaker 2: Patients on a larger dose showed did not improve. It's
- 2:45Speaker 2: something that analysts at RBC say is confounding. It also
- 2:48Speaker 2: really matters for this drug because they say what was
- 2:50Speaker 2: supposed to set this apart from competitors was more efficiency,
- 2:55Speaker 2: basically meaning a higher dose, you treat the disease better.
- 2:59Speaker 2: They also say, you know, this is broadly positive, these results,
- 3:03Speaker 2: but we just have to kind of pick apart what
- 3:05Speaker 2: that means, and it's not clear yet there.
- 3:07Speaker 3: Sounds like you had to do a little bit more research, right?
- 3:09Speaker 3: The lower dose versus the higher dose. All right, so
- 3:12Speaker 3: we're keeping an eye on that, and that stock's down
- 3:13Speaker 3: about two, almost 3% in today's session.
- 3:17Speaker 2: Salesforce. Yeah, so that's ticker CRM up about a percent
- 3:20Speaker 2: and a half after a double upgrade at Bank of America,
- 3:24Speaker 2: and they're pointing to AI. Not something we always hear
- 3:28Speaker 2: for software names, you know, AI as a tailwind. It's
- 3:30Speaker 2: actually something they say in that note. The firm says
- 3:33Speaker 2: they were pretty worried about AI disruption for Salesforce, but
- 3:36Speaker 2: they've come around on this. Now they think that big
- 3:39Speaker 2: companies are not going to be willing to just ditch
- 3:42Speaker 2: platforms that have all their data, all their workflows, their
- 3:44Speaker 2: compliance tools. And now they say Salesforce, it can continue
- 3:48Speaker 2: selling those. It can sell AI tools like CloudForce, AgentForce,
- 3:52Speaker 2: and maybe actually even capture more value. So they went
- 3:55Speaker 2: all the way from a sell equivalent rating to a buy,
- 3:58Speaker 2: and that is lifting the stock today.
- 4:01Speaker 3: There you have it. So that's interesting that it's actually
- 4:04Speaker 3: giving it a little bit of a kick to the upside.
- 4:06Speaker 1: Yeah, a lot of questions about a saspocalypse.
- 4:08Speaker 2: Stock's still down year to date. Remember, that's all we
- 4:11Speaker 2: were talking about for a while.
- 4:13Speaker 3: Not so much as of late.